Innovations in Drug Delivery - Broad-based Proprietary Technology Platforms to Address Delivery Efficiency and Improve Patient Compliance
Innovations in Drug Delivery - Broad-based ProprietaryTechnology Platforms to Address Delivery Efficiency andImprove Patient ComplianceReport Details:Published:September 2012No. of Pages: 69Price: Single User License – US$3500GBI Research, the leading business intelligence provider, has released its latest research,“Innovations in Drug Delivery - Broad-based Proprietary Technology Platforms to Address DeliveryEfficiency and Improve Patient Compliance”. The report provides an overview of the most excitinginnovations in drug delivery technologies in major therapeutic areas – oncology, vaccines,diabetes, rheumatology and respiratory diseases. Each chapter highlights emerging companieswith technologies that have the potential to transform drug delivery in that specific therapeuticarea. The report also explores the current environment in healthcare and the pharmaceuticalindustry, and examines drivers and challenges for the use of innovative drug deliverytechnologies.Drug delivery technologies provide commercial opportunities for pharmaceutical companies byimproving the chances of success for a drug development project. They enable the formulation ofa promising molecule that might have poor solubility or require selective delivery to a particulartissue, such as the brain. Similarly, drug delivery technologies may enable companies todifferentiate products within crowded therapeutic areas, facilitate life cycle management forexisting drugs, and reposition existing drugs – proprietary or generic – in new indications wherethe needs of the patient population are different or, again, where more targeted delivery isrequired. Products that are reformulated with novel drug delivery systems do not meet thetraditional criteria for innovative products – in other words, products that include new activemoieties. Nevertheless, GBI Research’s analysis shows that the commercial success of existingproducts that rely on innovative drug delivery technologies is clear, and these products makesignificant positive changes for patients.Scope•Detailed analysis of the reasons for the industry to look closely at drug delivery technologies.•Exploration of the environment in healthcare and the pharmaceutical industry that is driving companies to invest in drug delivery.
•Insight into collaborations between the largest pharmaceutical companies and smaller companies with innovative drug delivery technologies.•Detailed insight into innovation in drug delivery in key therapeutic areas: oncology, vaccines, diabetes, rheumatology and respiratory diseases.•Case studies of leading companies, their technologies and clinical data emerging from important drug development programs.Reasons to buy•Identify leading drug delivery companies.•Learn about mergers, acquisitions and collaborations in drug delivery.•Develop strategies and priorities for investing in drug delivery technologies.•Understand the most important technologies and companies involved in developing new drug delivery technologies in key therapeutic areas.•Explore the needs of patients in each therapeutic area and the ways in which drug delivery technologies can be used to meet these within drug development pipelines.Get your copy of this report @http://www.reportsnreports.com/reports/192515-innovations-in-drug-delivery-broad-based-proprietary-technology-platforms-to-address-delivery-efficiency-and-improve-patient-compliance.htmlMajor points covered in Table of Contents of this report includeTable of Contents1 Table of Contents 51.1 List of Tables 71.2 List of Figures 72 Drug Delivery - An Overview 82.1 Introduction 82.2 The Drug Delivery Market 112.3 Market Trends Affecting Drug Delivery 122.3.1 Drivers within the Healthcare Environment 122.3.2 Pharmaceutical Industry 132.4 Leading Drug Delivery Companies 142.4.1 Pharmaceutical Company Drug Delivery Portfolios 162.4.2 Deal Making 163 Oncology 203.1 Introduction 203.2 PEGylation 233.3 Protein-Based Drug Delivery Systems 243.3.1 Albumin 243.3.2 Other Fusion Proteins 25
3.3.3 Hyaluronidase 253.4 Nanoparticles for Drug Delivery 263.4.1 Liposomes 263.4.2 Dendrimers 273.4.3 Polymer Delivery Systems 273.5 Tumor Targeting 283.5.1 Antibody-Drug Conjugates 293.6 Conclusions 304 Vaccines 314.1 DNA Vaccines 314.1.1 DNA Vaccines Delivered in Viral Vectors 324.1.2 Bacterial and Yeast-Based Antigen Delivery 344.2 ‘Naked’ and Complexed DNA Vaccine Delivery 344.3 Vaccine Delivery to the Mucosal System and Skin 354.4 Intranasal Vaccine Delivery 354.5 Oral Vaccine Delivery 374.6 Transdermal Vaccine Delivery 394.6.1 Intercell 394.6.2 Microneedles for Intradermal Delivery 404.7 Conclusions 405 Diabetes 415.1 Introduction 415.2 Innovation in Insulin Delivery 415.2.1 Inhaled Insulin 415.2.2 Oral Insulin 435.2.3 Buccal Insulin 445.2.4 Transdermal Insulin 455.3 Next Generation Insulin Delivery Devices 455.3.1 Pens 455.3.2 Pumps 455.4 GLP-1 Analogues 465.5 Conclusions 486 Rheumatology 496.1 Introduction 496.2 Prefilled Syringes 506.3 Autoinjectors 506.3.1 New Materials in Autoinjector Design 526.4 Alternatives to Autoinjectors 536.4.1 Jet Injectors 53
6.4.2 Other Needle-Free Devices 546.4.3 Novel Injectors 556.5 Conclusions 557 Respiratory Diseases 577.1 Introduction 577.2 Drug Delivery Devices 577.2.1 Pressurized Metered Dose Inhalers 577.2.2 Dry Powder Inhalers 587.2.3 Aerosol Delivery Methods 587.2.4 Advances in Particle Engineering 607.2.5 Introduction of Electronics 617.3 Innovation in Drug Carriers for Pulmonary Drug Delivery 617.4 Alternative Routes of Delivery 617.5 Conclusions 628 Outlook 639 Appendix 659.1 Abbreviations 659.2 References 669.3 Methodology 689.3.1 Primary Research 689.3.2 Secondary Research 689.4 Contact Us 699.5 Disclaimer 69List of TablesTable 1: Innovation in Drug Delivery, Blockbuster Products Including Drug Delivery Systems, 201211Table 2: Innovation in Drug Delivery, Examples of Leading Drug Delivery Companies, 2012 15Table 3: Innovation in Drug Delivery, Examples of Licensing Deals for Drug Delivery, 2012 17Table 4: Innovation in Drug Delivery, Examples of Licensing Deals for Drug Delivery, 2012 18Table 5: Innovation in Drug Delivery, Examples of Oncology Drugs in Clinical Development withDrug Delivery Systems (by Technology Platform), 2012 21Table 6: Innovation in Drug Delivery, Advances in PEGylation Technologies, 2012 23Table 7: Innovation in Drug Delivery, Examples of Nanoparticulate Drug Delivery Systems, 201226Table 8: Innovation in Drug Delivery, Approved Cancer Drugs with Liposomal Delivery Systems,2012 26Table 9: Innovation in Drug Delivery, Companies Developing Viral Vector Delivery Systems for
Vaccines, 2012 33Table 10: Innovation in Drug Delivery, Companies Developing Intranasal Vaccines and theirTechnologies, 2012 36Table 11: Innovation in Drug Delivery, Companies Developing Oral Vaccines and theirTechnologies, 2012 38Table 12: Innovation in Drug Delivery, Companies Developing Transdermal Vaccines and theirTechnologies, 2012 39Table 13: Innovation in Drug Delivery, Inhaled Insulin Products and their Development Status,2012 42Table 14: Innovation in Drug Delivery, Oral Insulin Products and their Development Status, 201243Table 15: Innovation in Drug Delivery, GLP-1 Analogs and their Development Status, 2012 47Table 16: Innovation in Drug Delivery, Leading Drugs for Arthritis and their Delivery Systems, 201249Table 17: Innovation in Drug Delivery, Leading Autoinjector Manufacturers and their Products,2012 51Table 18: Innovation in Drug Delivery, Examples of Liquid Jet Injectors for Needle Free Delivery,2012 53Table 19: Innovation in Drug Delivery, Companies Commercializing Aerosol Drug DeliveryTechnologies, 2012 59Table 20: Innovation in Drug Delivery, Drug Delivery Requirements in Different Therapeutic Areas,2012 63List of FiguresFigure 1: Innovation in Drug Delivery, Commonly Used Options for Drug Delivery, 2012 8Figure 2: Innovation in Drug Delivery, Uses of Drug Delivery Technology, 2012 9Figure 3: Innovation in Drug Delivery, Commercial Opportunities for Drug Delivery Systems, 201210Figure 4: Innovation in Drug Delivery, Reducing Drug Toxicity Through Drug Delivery, 2012 20Contact: firstname.lastname@example.org for more information.